Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neurilemmoma 1Neoplasm Metastasis 1Multiple Myeloma 1Meningioma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Doxorubicin 69Radiotherapy 50Ifosfamide 48Gemcitabine 43Cyclophosphamide 36pazopanib 29Filgrastim 28pembrolizumab 26Docetaxel 26Nivolumab 23Surgical Procedures, Operative 21Etoposide 21Cisplatin 21Trabectedin 19Blood Specimen Collection 19Carboplatin 15Radiation 14Magnetic Resonance Spectroscopy 14Vincristine 13Bevacizumab 13anlotinib 12Temozolomide 12Peripheral Blood Stem Cell Transplantation 12Ipilimumab 12liposomal doxorubicin 11apatinib 11Radiosurgery 11Neoadjuvant Therapy 11Melphalan 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma × HDAC-42 × Clear all
NCT02795819 2019-10-24

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Virginia Commonwealth University

Phase 1 Terminated
6 enrolled 12 charts
GenitourinarySarcoma

Carcinoma, Renal Cell, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡